X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs STERLING BIOTECH - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE STERLING BIOTECH CADILA HEALTHCARE/
STERLING BIOTECH
 
P/E (TTM) x 32.4 -2.0 - View Chart
P/BV x 6.4 0.1 8,188.1% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CADILA HEALTHCARE   STERLING BIOTECH
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
STERLING BIOTECH
Dec-13
CADILA HEALTHCARE/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs46011 4,381.0%   
Low Rs3053 8,970.6%   
Sales per share (Unadj.) Rs92.126.8 343.6%  
Earnings per share (Unadj.) Rs14.8-15.0 -99.1%  
Cash flow per share (Unadj.) Rs18.5-5.5 -338.3%  
Dividends per share (Unadj.) Rs3.200-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs68.054.9 123.9%  
Shares outstanding (eoy) m1,023.74267.87 382.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.20.3 1,601.7%   
Avg P/E ratio x25.8-0.5 -5,555.8%  
P/CF ratio (eoy) x20.7-1.3 -1,626.9%  
Price / Book Value ratio x5.60.1 4,442.8%  
Dividend payout %21.60-   
Avg Mkt Cap Rs m391,5811,862 21,033.5%   
No. of employees `00016.91.4 1,244.8%   
Total wages/salary Rs m15,002547 2,743.6%   
Avg. sales/employee Rs Th5,594.55,303.3 105.5%   
Avg. wages/employee Rs Th890.1403.8 220.4%   
Avg. net profit/employee Rs Th899.9-2,959.0 -30.4%   
INCOME DATA
Net Sales Rs m94,2957,181 1,313.2%  
Other income Rs m1,28643 3,018.8%   
Total revenues Rs m95,5817,223 1,323.2%   
Gross profit Rs m19,036947 2,010.3%  
Depreciation Rs m3,7502,543 147.5%   
Interest Rs m4504,377 10.3%   
Profit before tax Rs m16,122-5,931 -271.8%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,289-1,924 -67.0%   
Profit after tax Rs m15,168-4,007 -378.6%  
Gross profit margin %20.213.2 153.1%  
Effective tax rate %8.032.4 24.6%   
Net profit margin %16.1-55.8 -28.8%  
BALANCE SHEET DATA
Current assets Rs m60,22314,335 420.1%   
Current liabilities Rs m53,05849,809 106.5%   
Net working cap to sales %7.6-494.0 -1.5%  
Current ratio x1.10.3 394.4%  
Inventory Days Days70403 17.3%  
Debtors Days Days88171 51.7%  
Net fixed assets Rs m72,98455,432 131.7%   
Share capital Rs m1,024268 382.2%   
"Free" reserves Rs m68,57613,935 492.1%   
Net worth Rs m69,60014,701 473.4%   
Long term debt Rs m24,6849,478 260.4%   
Total assets Rs m152,20773,988 205.7%  
Interest coverage x36.8-0.4 -10,374.8%   
Debt to equity ratio x0.40.6 55.0%  
Sales to assets ratio x0.60.1 638.3%   
Return on assets %10.30.5 2,048.6%  
Return on equity %21.8-27.3 -80.0%  
Return on capital %17.9-6.4 -279.1%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m21,2801,860 1,144.2%   
Fx outflow Rs m10,87425 43,688.2%   
Net fx Rs m10,4061,835 567.1%   
CASH FLOW
From Operations Rs m13,4951,719 785.2%  
From Investments Rs m-29,103-3,148 924.4%  
From Financial Activity Rs m23,1581,426 1,624.0%  
Net Cashflow Rs m7,556-3 -222,235.3%  

Share Holding

Indian Promoters % 74.8 33.9 220.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.0 -  
FIIs % 5.9 9.9 59.6%  
ADR/GDR % 0.0 16.9 -  
Free float % 11.0 39.3 28.0%  
Shareholders   44,069 21,482 205.1%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  UNICHEM LAB  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 16, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - TORRENT PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS